Unknown

Dataset Information

0

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.


ABSTRACT: The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas. The control cohort consisted of age- and sex-matched patients without lymphoma who were hospitalized because of COVID-19. We performed detailed clinical analyses, in-depth cellular and molecular immune profiling, and comprehensive virological studies in 12 patients with available biospecimens. B-cell depleted lymphoma patients had more severe and protracted clinical course (median hospitalization 88 versus 17 d). All patients actively receiving immunochemotherapy (n = 5) required ICU support including long-term mechanical ventilation. Neutrophil recovery following granulocyte colony stimulating factor stimulation coincided with hyperinflammation and clinical deterioration in 4 of the 5 patients. Immune cell profiling and gene expression analysis of peripheral blood mononuclear cells revealed early activation of monocytes/macrophages, neutrophils, and the complement system in B-cell depleted lymphoma patients, with subsequent exacerbation of the inflammatory response and dysfunctional interferon signaling at the time of clinical deterioration of COVID-19. Longitudinal immune cell profiling and functional in vitro assays showed SARS-CoV-2-specific CD8+ and CD4+ T-effector cell responses. Finally, we observed long-term detection of SARS-CoV-2 in respiratory specimens (median 84 versus 12 d) and an inability to mount lasting SARS-CoV-2 antibody responses in B-cell depleted lymphoma patients. In summary, we identified clinically relevant particularities of COVID-19 in lymphoma patients receiving B-cell depleting immunochemotherapies.

SUBMITTER: Gaitzsch E 

PROVIDER: S-EPMC8240782 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.

Gaitzsch Erik E   Passerini Verena V   Khatamzas Elham E   Strobl Carolin D CD   Muenchhoff Maximilian M   Scherer Clemens C   Osterman Andreas A   Heide Michael M   Reischer Anna A   Subklewe Marion M   Leutbecher Alexandra A   Tast Benjamin B   Ruhle Adrian A   Weiglein Tobias T   Stecher Stephanie-Susanne SS   Stemmler Hans J HJ   Dreyling Martin M   Girl Philipp P   Georgi Enrico E   Wölfel Roman R   Mateyka Laura L   D'Ippolito Elvira E   Schober Kilian K   Busch Dirk H DH   Kager Juliane J   Spinner Christoph D CD   Treiber Matthias M   Rasch Sebastian S   Lahmer Tobias T   Iakoubov Roman R   Schneider Jochen J   Protzer Ulrike U   Winter Christof C   Ruland Jürgen J   Quante Michael M   Keppler Oliver T OT   von Bergwelt-Baildon Michael M   Hellmuth Johannes J   Weigert Oliver O  

HemaSphere 20210628 7


The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas. The control cohort consisted of age- and sex-matched patients without lymphoma who were hospitalized because of COVID-19. We performed detailed clinical analyses, in-depth cellular and molecular immune profiling, and  ...[more]

Similar Datasets

| S-EPMC10789957 | biostudies-literature
| S-EPMC11408186 | biostudies-literature
| S-EPMC7405500 | biostudies-literature
| S-EPMC9388928 | biostudies-literature
| S-EPMC8530768 | biostudies-literature
| S-EPMC8093997 | biostudies-literature
| S-EPMC11788169 | biostudies-literature
2015-07-16 | GSE66166 | GEO
| S-EPMC10089694 | biostudies-literature